Compare DexCom, Inc. (DXCM) vs Workiva Inc (WK) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Workiva (WK) trades at $54.91, up 2.27% with strong technical momentum and bullish moving average signals. The company demonstrates robust revenue growth with Q1 2026 EPS beating estimates at $0.77 versus $0.66 expected, while maintaining a high gross margin of 79.4%. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and an $71 consensus price target, representing 29% upside potential from current levels.

WK offers compelling growth prospects with expanding profitability and dominant market positioning in compliance software, though elevated valuation multiples (P/E 226.58) and technical overbought conditions warrant caution. The stock faces execution risks in maintaining growth momentum amid competitive pressures, but strong institutional support and consistent earnings beats support the bullish outlook.